Search Result

Results for "

PKD

" in MedChemExpress (MCE) Product Catalog:

By Targets:	PKD (15) 5-HT Receptor (6) Adrenergic Receptor (2) Apoptosis (3) Aquaporin (2) Drug Metabolite (1) E3 Ligase Ligand-Linker Conjugates (1) Epigenetic Reader Domain (2) Histamine Receptor (2) Histone Methyltransferase (2) Isotope-Labeled Compounds (1) Motilin Receptor (3) nAChR (1) NEKs (1) PDK-1 (1) Pim (3) PKC (1) PROTACs (2) Pyruvate Kinase (3) Small Interfering RNA (siRNA) (10)
By Research Areas:	Cancer (17) Cardiovascular Disease (3) Endocrinology (2) Inflammation/Immunology (5) Metabolic Disease (10) Neurological Disease (12)
Oligonucleotides:	Pre-designed siRNA Sets (10) siRNAs (10)

Inhibitors & Agonists

Screening Libraries

Peptides

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Oligonucleotides

Targets Recommended: PKD

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-131962A

PKD-IN-1 dihydrochloride	PDK-1	Metabolic Disease Cancer
PKD-IN-1 dihydrochloride (compound 32), an aminoethylamino-aryl (AEAA) compound, acts as *PKD-1* inhibitor. PKD-IN-1 can be used for protein kinase D (PKD)-mediated diseases research .

HY-131962

PKD-IN-1	PKD	Metabolic Disease Cancer
PKD-IN-1 (compound 32), an aminoethylamino-aryl (AEAA) compound, acts as *PKD-1* inhibitor. PKD-IN-1 can be used for protein kinase D (PKD)-mediated diseases research .

HY-RS00002

Pkd1 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA) PKD	Others
Pkd1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Pkd1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Pkd1 Mouse Pre-designed siRNA Set A Pkd1 Mouse Pre-designed siRNA Set A

HY-RS00003

PKD1 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA) PKD	Others
PKD1 Human Pre-designed siRNA Set A contains three designed siRNAs for PKD1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

PKD1 Human Pre-designed siRNA Set A PKD1 Human Pre-designed siRNA Set A

HY-RS00004

Pkd1 Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA) PKD	Others
Pkd1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Pkd1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Pkd1 Rat Pre-designed siRNA Set A Pkd1 Rat Pre-designed siRNA Set A

HY-RS10591

PKD2 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
PKD2 Human Pre-designed siRNA Set A contains three designed siRNAs for PKD2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

PKD2 Human Pre-designed siRNA Set A PKD2 Human Pre-designed siRNA Set A

HY-RS10592

Pkd2 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Pkd2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Pkd2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Pkd2 Mouse Pre-designed siRNA Set A Pkd2 Mouse Pre-designed siRNA Set A

HY-RS10593

Pkd2 Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Pkd2 Rat Pre-designed siRNA Set A contains three designed siRNAs for Pkd2 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Pkd2 Rat Pre-designed siRNA Set A Pkd2 Rat Pre-designed siRNA Set A

HY-RS00005

PKD1L1 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
PKD1L1 Human Pre-designed siRNA Set A contains three designed siRNAs for PKD1L1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

PKD1L1 Human Pre-designed siRNA Set A PKD1L1 Human Pre-designed siRNA Set A

HY-RS00006

PKD1L2 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
PKD1L2 Human Pre-designed siRNA Set A contains three designed siRNAs for PKD1L2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

PKD1L2 Human Pre-designed siRNA Set A PKD1L2 Human Pre-designed siRNA Set A

HY-RS00007

PKD1L3 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
PKD1L3 Human Pre-designed siRNA Set A contains three designed siRNAs for PKD1L3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

PKD1L3 Human Pre-designed siRNA Set A PKD1L3 Human Pre-designed siRNA Set A

HY-RS10594

PKD2L1 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
PKD2L1 Human Pre-designed siRNA Set A contains three designed siRNAs for PKD2L1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

PKD2L1 Human Pre-designed siRNA Set A PKD2L1 Human Pre-designed siRNA Set A

HY-128142

*PKC/PKD-IN-1*	PKD PKC	Cardiovascular Disease
PKC/PKD-IN-1 (Compound 13C) is an orally active dual protein kinase C/D (PKC/PKD) inhibitor with an IC₅₀ value of 0.6 nM for *PKD1. PKC/PKD*-IN-1 can attenuate high-salt diet-induced cardiac hypertrophy and can be used in the study of heart failure .

HY-12239

CID755673 5+ Cited Publications	PKD	Cancer
CID755673 is a potent *PKD* inhibitor with IC₅₀s of 182 nM, 280 nM and 227 nM for *PKD1, PKD2* and *PKD3*, respectively.

HY-13454

CID 2011756	PKD	Cancer
CID 2011756 is an ATP competitive *PKD* inhibitor, with an IC₅₀ of 3.2 μM for PKD1 in cell free assay, and also shows cellular pan-PKD inhibitory activity against PKD2 and PKD3 (IC₅₀, 0.6 and 0.7 μM, respectively). CID 2011756 also has antitumor activity.

HY-118052

BPKDi	PKD	Cardiovascular Disease
BPKDi is a potent bipyridyl *PKD* inhibitor with IC₅₀s of 1 nM, 9 nM and 1 nM for PKD1, PKD2 and PKD3, respectively. BPKDi blocks signal-dependent phosphorylation and nuclear export of class IIa HDACs in cardiomyocytes .

HY-15528

kb NB 142-70	PKD	Cancer
kb NB 142-70 is a potent *PKD* inhibitor, with IC₅₀s of 28.3, 58.7 and 53.2 nM for PKD1, PKD2, and PKD3, respectively. kb NB 142-70 also has antitumor activity.

HY-112547

CRT5 CRT0066051	PKD	Others
CRT5, a pyrazine benzamide, is a potent and selective inhibitor for all three isoforms of *PKD* in endothelial cells treated with VEGF (IC₅₀s = 1, 2, and 1.5 nM for PKD1, PKD2, and PKD3, respectively). CRT5 decreases VEGF-induced endothelial migration, proliferation and tubulogenesis .

HY-151374

3-IN-PP1	PKD	Cancer
3-IN-PP1 is a protein kinase D (PKD) inhibitor. 3-IN-PP1 has potent pan-PKD inhibitory activity for PKD1, PKD2 and PKD3 with IC₅₀ values of 108, 94 and 108 nM, respectively. 3-IN-PP1 also is a broad spectrum anticancer agent and has inhibition of several tumor cells growth. 3-IN-PP1 can be used for the research of cancer .

HY-15698A

CRT0066101 dihydrochloride 2 Publications Verification	PKD Pim Apoptosis	Inflammation/Immunology Cancer
CRT0066101 dihydrochloride is a potent and orally active *PKD* inhibitor with IC₅₀ values of 1 nM, 2.5 nM and 2 nM for *PKD1, PKD2, and PKD3, respectively . CRT0066101 dihydrochloride is also a potent PIM2* inhibitor with an IC₅₀ of ~135.7 nM. CRT0066101 dihydrochloride exhibits anti-inflammatory activity in mice LPS (HY-D1056)-induced lung injury models, and has anticancer effects .

HY-15698

CRT0066101 2 Publications Verification	PKD Pim Apoptosis	Inflammation/Immunology Cancer
CRT0066101 is a potent and orally active *PKD* inhibitor with IC₅₀ values of 1 nM, 2.5 nM and 2 nM for *PKD1, PKD2, and PKD3, respectively . CRT0066101 is also a potent PIM2* inhibitor with an IC₅₀ of ~135.7 nM. CRT0066101 exhibits anti-inflammatory activity in mice LPS (HY-D1056)-induced lung injury models, and has anticancer effects .

HY-15698B

CRT0066101 trihydrochloride	PKD Pim Apoptosis	Inflammation/Immunology Cancer
CRT0066101 trihydrochloride is the trihydrochloride salt form of CRT0066101 (HY-15698). CRT0066101 trihydrochloride is an orally active *PKD* inhibitor with IC₅₀ values of 1 nM, 2.5 nM and 2 nM for *PKD1, PKD2, and PKD3, respectively. CRT0066101 trihydrochloride is also an inhibitor for PIM2* with an IC₅₀ of ~135.7 nM. CRT0066101 trihydrochloride exhibits anti-inflammatory activity in mice LPS (HY-D1056)-induced lung injury models, and has anticancer effects .

HY-151372

Protein kinase D inhibitor 1	PKD	Cancer
Protein kinase D inhibitor 1 (compound 17m) is a pan-PKD inhibitor, with IC₅₀ values ranging from 17 to 35 nM. Protein kinase D inhibitor 1 inhibits PKD-dependent cortactin phosphorylation .

HY-103199

Carpindolol SDZ21009	5-HT Receptor	Neurological Disease
Carpindolol (SDZ21009) is a 5-HT1B receptor antagonist (pK_d of 8.53 and pK_B of 8.0) and a 5-HT1D receptor agonist (pEC₅₀ of 5.91 and *pK_d* of 6.37) .

HY-16698

kb-NB77-78	Others	Cancer
kb-NB77-78 is an analogue of CID797718, but shows no PKD inhibitory activity .

HY-138563

GSK973	Epigenetic Reader Domain	Cancer
GSK973 is a highly selective, orally bioavailable inhibitor of the BD2s (second bromodomains) of the BET family, with a pIC₅₀ of 7.8 and a *pK_d* of 8.7 for BRD4 BD2. GSK973 displays a 1600-fold selectivity for BRD4 BD2 over BRD4 BD1. GSK973 shows good potency against BRD2 BD2, BRD3 BD2, and BRDT BD2 (pIC₅₀=7.4~7.8; pK_d=8.3~8.5) .

HY-103197

2-Methoxyidazoxan monohydrochloride RX821002 hydrochloride	Adrenergic Receptor	Neurological Disease
2-Methoxyidazoxan monohydrochloride (RX821002 hydrochloride) is a highly selective alpha 2-adrenoceptor antagonist with little or no imidazoline antagonist effect. RX 821002 has markedly higher affinity for (guinea-pig) alpha 2D-adrenoceptors (pK_d 9.7) than for (rabbit) alpha 2A-adrenoceptors (pK_d 8.2) .

HY-14557

Pimavanserin Maximum Cited Publications 12 Publications Verification ACP-103	5-HT Receptor	Neurological Disease
Pimavanserin is a selective inverse agonist of the 5-HT2A receptor with pIC₅₀ and *pK_d* of 8.73 and 9.3, respectively.

HY-N2057

Steviol	Aquaporin	Metabolic Disease
Steviol is a major metabolite of the sweetening compound stevioside. Steviol slows renal cyst growth by reducing AQP2 expression and promoting AQP2 degradation .

HY-N2057R

Steviol (Standard)	Aquaporin	Metabolic Disease
Steviol (Standard) is the analytical standard of Steviol. This product is intended for research and analytical applications. Steviol is a major metabolite of the sweetening compound stevioside. Steviol slows renal cyst growth by reducing AQP2 expression and promoting AQP2 degradation .

HY-P1233

ANQ-11125	Motilin Receptor	Metabolic Disease
ANQ-11125 is a potent and selective antagonist of motilin, with the *pK_d* of 8.24. ANQ-11125 blocks motilide-induced contractions in vitro in the rabbit .

HY-114204

GSK8814	Epigenetic Reader Domain	Cancer
GSK8814 is a potent, selective, and ATAD2/2B bromodomain chemical probe and inhibitor, with a binding constant *pK_d*=8.1 and a pK_i=8.9 in BROMOscan. GSK8814 binds to ATAD2 and BRD4 BD1 with pIC₅₀s of 7.3 and 4.6, respectively. GSK8814 shows 500-fold selectivity for ATAD2 over BRD4 BD1 .

HY-P1233A

ANQ-11125 TFA	Motilin Receptor	Metabolic Disease
ANQ-11125 TFA is a potent and selective antagonist of motilin, with the *pK_d* of 8.24. ANQ-11125 TFA blocks motilide-induced contractions in vitro in the rabbit .

HY-135392

N-Desmethyl Pimavanserin AC-279	Drug Metabolite	Neurological Disease
N-Desmethyl Pimavanserin is the active metabolite of Pimavanserin. Pimavanserin is a selective inverse agonist of the 5-HT2A receptor with pIC₅₀ and pK_d of 8.73 and 9.3, respectively.

HY-117051

STA-2842	Others	Cancer
STA-2842 is a small molecule agent that inhibits heat shock protein 90 (HSP90) to treat autosomal dominant polycystic kidney disease (ADPKD). The disease is caused by inherited mutations in the PKD1 or PKD2 genes that aberrantly activate multiple signaling proteins and pathways that regulate cell proliferation. Through network construction, we found that many HSP90 client proteins associated with ADPKD are regulated by HSP90. STA-2842 induced degradation of these clients in Pkd1?/? primary kidney cells and in vivo. In experiments using conditional Cre-mediated in vivo knockout of Pkd1 in mice, we found that weekly administration of STA-2842 for 10 weeks significantly reduced initial renal cyst formation and kidney growth in mice and slowed disease progression in mice with pre-existing cysts. These improved disease phenotypes were accompanied by improvements in renal function markers and reductions in the expression and activity of HSP90 clients and their effectors, with the extent of this inhibition correlating with the extent of cyst expansion in individual animals. Pharmacokinetic analysis showed that HSP90 was overexpressed in cystic kidney tissue and HSP90 inhibitors were selectively retained in cystic tissue, which is similar to the situation in solid tumors. These results provide a preliminary basis for evaluating HSP90 inhibitors as therapeutic agents for ADPKD.

HY-B1281

Mepyramine maleate 2 Publications Verification Pyrilamine maleate	Histamine Receptor	Neurological Disease Endocrinology
Mepyramine maleate, a first generation antihistamine, is an antagonist of histamine H1 receptor, with K_ds of 0.8 nM, 5200 nM and >3000 nM for H1, H2, and H3 receptor, respectively, and a *pK_d* of 9.4 for H1 receptor.

HY-14557R

Pimavanserin (Standard)	5-HT Receptor	Neurological Disease
Pimavanserin (Standard) is the analytical standard of Pimavanserin. This product is intended for research and analytical applications. Pimavanserin is a selective inverse agonist of the 5-HT2A receptor with pIC₅₀ and *pK_d* of 8.73 and 9.3, respectively.

HY-130614

PROTAC EED degrader-1	PROTACs Histone Methyltransferase	Cancer
PROTAC EED degrader-1 is a von Hippel-Lindau-based PROTAC targeting EED with a *pK_D* of 9.02. PROTAC EED degrader-1 is a polycomb repressive complex 2 (PRC2) inhibitor (pIC₅₀=8.17) targeting the EED subunit .

HY-130615

PROTAC EED degrader-2	PROTACs Histone Methyltransferase	Cancer
PROTAC EED degrader-2 is a von Hippel-Lindau-based PROTAC targeting EED with a *pK_D* of 9.27. PROTAC EED degrader-2 is a polycomb repressive complex 2 (PRC2) inhibitor (pIC₅₀=8.11) targeting the EED subunit .

HY-12689

Mitapivat 1 Publications Verification AG-348	Pyruvate Kinase	Metabolic Disease
Mitapivat (AG-348) is an orally active pyruvate kinase allosteric activator. Mitapivat increases enzymatic activity, protein stability, and ATP levels over a broad range of PKLR genotypes, shows the potential to restore the activity of PK (pyruvate kinase)-deficient glycolytic pathways. Mitapivat can be used in study of PK deficiency .

HY-12689A

Mitapivat hemisulfate sesquihydrate AG-348 hemisulfate sesquihydrate	Pyruvate Kinase	Metabolic Disease
Mitapivat hemisulfate sesquihydrate (AG-348) is an orally active pyruvate kinase allosteric activator. Mitapivat increases enzymatic activity, protein stability, and ATP levels over a broad range of PKLR genotypes, shows the potential to restore the activity of PK (pyruvate kinase)-deficient glycolytic pathways. Mitapivat can be used in study of PK deficiency .

HY-12689B

Mitapivat hemisulfate AG-348 hemisulfate	Pyruvate Kinase	Metabolic Disease
Mitapivat hemisulfate is an orally active pyruvate kinase allosteric activator. Mitapivat hemisulfate increases enzymatic activity, protein stability, and ATP levels over a broad range of PKLR genotypes, shows the potential to restore the activity of PK (pyruvate kinase)-deficient glycolytic pathways. Mitapivat hemisulfate can be used in study of PK deficiency .

HY-B1281R

Mepyramine maleate (Standard)	Histamine Receptor	Neurological Disease Endocrinology
Mepyramine maleate (Standard) is the analytical standard of Mepyramine maleate. This product is intended for research and analytical applications. Mepyramine maleate, a first generation antihistamine, is an antagonist of histamine H1 receptor, with Kds of 0.8 nM, 5200 nM and >3000 nM for H1, H2, and H3 receptor, respectively, and a pKd of 9.4 for H1 receptor.

HY-106258

Atilmotin OHM 11638; BAX-ACC 1638; MOT 288	Motilin Receptor	Metabolic Disease
OHM 11638 (Atilmotin), an analogue of the (1-14) fragment of porcine motilin, is a motilin receptor agonist with a *pK_d* of 8.94 for the motilin receptor. OHM 11638 affects esophageal, lower esophageal sphincter (LES), and gastric motility. OHM 11638 increases LES and gastric pressures, OHM 11638 can be used as prokinetic agents .

HY-144425

BSc5367	NEKs	Inflammation/Immunology
BSc5367 is a potent Nek1 inhibitor with an IC₅₀ of 11.5 nM. NIMA-related protein kinase Nek1 is crucially involved in cell cycle regulation, DNA repair and microtubule regulation and dysfunctions of Nek1 play key roles in amyotrophic lateral sclerosis (ALS), polycystic kidney disease (PKD) and several types of radiotherapy resistant cancer .

HY-135392S

N-Desmethyl Pimavanserin-d9 hydrochloride AC-279-d₉ hydrochloride	Isotope-Labeled Compounds	Neurological Disease
N-Desmethyl Pimavanserin-d9 hydrochloride (AC-279-d9 hydrochloride) is the deuterium labeled N-Desmethyl Pimavanserin (HY-135392). N-Desmethyl Pimavanserin is the active metabolite of Pimavanserin. Pimavanserin is a selective inverse agonist of the 5-HT2A receptor with pIC₅₀ and pK_d of 8.73 and 9.3, respectively .

HY-19490

VQW-765 AQW-051	nAChR	Neurological Disease
VQW-765 (AQW-051) is a selective and orally active alpha-7 nicotinic acetylcholine receptor (α7-nAChR) agonist with a pK_D value of 7.56 to recombinantly expressed human α7-nAChR. VQW-765 shows anxiolytic-like effect in vivo. VQW-765 can be used for the research of anxiety disorder and acute performance anxiety .

HY-12709A

ARC 239 dihydrochloride	Adrenergic Receptor	Cardiovascular Disease Inflammation/Immunology
ARC 239 dihydrochloride is a selective α2B/2C adrenoceptor antagonist (pK_d values are 5.95, 7.41 and 7.56 at α2A, α2B, and α2C receptors respectively). ARC 239 dihydrochloride binds to CHO cell membranes expressing human recombinant a2A-, a2B- or a2C-adrenoceptor subtypes with pK_is of 5.6, 8.4, and 7.08, respectively .

HY-130816

(S,R,S)-AHPC-O-Ph-PEG1-NH2 VH032-O-Ph-PEG1-NH2	E3 Ligase Ligand-Linker Conjugates	Cancer
(S,R,S)-AHPC-O-Ph-PEG1-NH2 (VH032-O-Ph-PEG1-NH2) is E3 ligase ligand-linker conjugate and incorporates a VHL ligand for the E3 ubiquitin ligase, and a PROTAC linker. (S,R,S)-AHPC-O-Ph-PEG1-NH2 is used in PROTAC EED degrader-1 (HY-130614). PROTAC EED degrader-1 is a PROTAC targeting EED with a pK_D of 9.02 .

HY-101009

Methiothepin maleate Metitepine maleate; Ro-8-6837 maleate	5-HT Receptor	Neurological Disease
Methiothepin maleate is a potent and non-selective 5-HT₂ receptor antagonist, with pK_ds of 7.10 (5-HT_1A), 7.28 (5HT_1B), 7.56 (5HT_1C), 6.99 (5HT_1D), 7.0 (5-HT_5A), 7.8 (5-HT_5B), 8.74 (5-HT₆), and 8.99 (5-HT₇), and pK_is of 8.50 (5HT_2A), 8.68 (5HT_2B), and 8.35 (5HT_2C).

Cat. No.	Product Name

HY-L003

Apoptosis Compound Library

2,352 compounds

Apoptosis is an ordered and orchestrated cellular process that occurs in physiological and pathological conditions, which is also called programmed cell death (PCD). Apoptosis plays a crucial role in developing and maintaining the health of the body by eliminating old cells, unhealthy cells and unnecessary cells. Too little or too much apoptosis contribute to many diseases. When apoptosis does not work correctly, cells that should be eliminated may persist and become immortal, for example, in cancer and leukemia. When apoptosis works overly well, it kills too many cells and inflicts grave tissue damage. This is the case in strokes and neurodegenerative disorders such as Alzheimer's, Huntington's, and Parkinson's disease.

MCE designs a unique collection of 2,352 apoptosis-related compounds mainly focusing on the key targets in the apoptosis signaling pathway and can be used in the research of apoptosis signal pathway and related diseases.

Cat. No.	Product Name	Target	Research Area

HY-P1233

ANQ-11125	Motilin Receptor	Metabolic Disease
ANQ-11125 is a potent and selective antagonist of motilin, with the *pK_d* of 8.24. ANQ-11125 blocks motilide-induced contractions in vitro in the rabbit .

HY-P1233A

ANQ-11125 TFA	Motilin Receptor	Metabolic Disease
ANQ-11125 TFA is a potent and selective antagonist of motilin, with the *pK_d* of 8.24. ANQ-11125 TFA blocks motilide-induced contractions in vitro in the rabbit .

HY-106258

Atilmotin OHM 11638; BAX-ACC 1638; MOT 288	Motilin Receptor	Metabolic Disease
OHM 11638 (Atilmotin), an analogue of the (1-14) fragment of porcine motilin, is a motilin receptor agonist with a *pK_d* of 8.94 for the motilin receptor. OHM 11638 affects esophageal, lower esophageal sphincter (LES), and gastric motility. OHM 11638 increases LES and gastric pressures, OHM 11638 can be used as prokinetic agents .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N2057

Steviol	Other Terpenoids Structural Classification other families Classification of Application Fields Terpenoids Source classification Metabolic Disease Plants Disease Research Fields Sweeteners Food Research	Aquaporin
Steviol is a major metabolite of the sweetening compound stevioside. Steviol slows renal cyst growth by reducing AQP2 expression and promoting AQP2 degradation .

HY-N2057R

Steviol (Standard)	Other Terpenoids Structural Classification other families Terpenoids Source classification Plants	Aquaporin
Steviol (Standard) is the analytical standard of Steviol. This product is intended for research and analytical applications. Steviol is a major metabolite of the sweetening compound stevioside. Steviol slows renal cyst growth by reducing AQP2 expression and promoting AQP2 degradation .

Cat. No.	Compare	Product Name	Species	Source

HY-P74615

	Protein Kinase D2/PRKD2 Protein, Human (sf9, His-GST) Serine/threonine-protein kinase D2; PRKD2; PKD2; HSPC187	Human	Sf9 insect cells
	Protein kinase D2 (PRKD2) is a serine/threonine protein kinase that mediates various cellular processes downstream of PKC. It affects cell proliferation through MAPK1/3 (ERK1/2) signaling, activates NF-kappa-B under oxidative stress, inhibits HDAC7 transcriptional repression, and regulates T cell antigen receptor (TCR) signaling, cytokine production, Golgi trafficking, angiogenesis, particle release, and cell adhesion. Protein Kinase D2/PRKD2 Protein, Human (sf9, His-GST) is the recombinant human-derived protein Kinase D2/PRKD2 protein, expressed by Sf9 insect cells , with N-His, N-GST labeled tag.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-135392S

N-Desmethyl Pimavanserin-d9 hydrochloride
N-Desmethyl Pimavanserin-d9 hydrochloride (AC-279-d9 hydrochloride) is the deuterium labeled N-Desmethyl Pimavanserin (HY-135392). N-Desmethyl Pimavanserin is the active metabolite of Pimavanserin. Pimavanserin is a selective inverse agonist of the 5-HT2A receptor with pIC₅₀ and pK_d of 8.73 and 9.3, respectively .

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P81914

	PKD1 Antibody (YA1659) PRKD1; PKD; PKD1; PRKCM; Serine/threonine-protein kinase D1; Protein kinase C mu type; Protein kinase D; nPKC-D1; nPKC-mu	WB	Human, Rat
	PKD1 Antibody (YA1659) is a biotin-conjugated non-conjugated IgG antibody, targeting PKD1, with a predicted molecular weight of 102 kDa (observed band size: 102 kDa). PKD1 Antibody (YA1659) can be used for WB experiment in human, rat background.

HY-P81985

	PKD2 Antibody (YA1730) PRKD2; PKD2; HSPC187; Serine/threonine-protein kinase D2; nPKC-D2	WB, IHC-P, ICC/IF, FC	Human, Mouse
	PKD2 Antibody (YA1730) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA1730), targeting PKD2, with a predicted molecular weight of 97 kDa (observed band size: 105 kDa). PKD2 Antibody (YA1730) can be used for WB, IHC-P, ICC/IF, FC experiment in human, mouse background.

HY-P81917

	Phospho-PRKD2 (Ser876) Antibody (YA1662) PRKD2; PKD2; HSPC187; Serine/threonine-protein kinase D2; nPKC-D2	WB, IP	Human
	Phospho-PRKD2 (Ser876) Antibody (YA1662) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA1662), targeting Phospho-PRKD2 (Ser876), with a predicted molecular weight of 97 kDa (observed band size: 105 kDa). Phospho-PRKD2 (Ser876) Antibody (YA1662) can be used for WB, IP experiment in human background.